retatrutide 2025 and the Grey Market: Buyer Beware – Sarah Hormachea Some Providers Prescribe Unapproved Retatrutide

After sifting through numerous gut hormones, the two researchers concentrated their efforts on glucagon because they knew it had multiple targets

Medical oversight (30%): Whether a licensed clinician reviews labs, adjusts dosing, and is reachable for side effects

Geographic variations also impact the cost equation

Plateaus are normal and do not indicate treatment failure

Novel perspectives on the link between obesity and cancer risk: from mechanisms to clinical implications

The company received positive end-of-Phase 2 feedback from the FDA and has indicated that Phase 3 initiation is on track for the third quarter of 2026